8-15-1　ⓔ文献

  1. 武田憲文：遺伝性胸部大動脈瘤・解離症．医学のあゆみ，2019; 268: 789–794.

  2. Dietz HC, Cutting GR, et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature, 1991; 352: 337–339.

  3. Takeda N, Hara H, et al: TGF–beta signaling–related genes and Thoracic aortic aneurysms and dissections. Int J Mol Sci, 2018; 19: 2125.

  4. 八木宏樹，武田憲文：Marfan症候群における大動脈瘤形成機序．Cutting Edge of Molecular Cardiology：新しい臨床を開拓するための分子循環器病学，南山堂，2019; 190–195.

  5. Habashi JP, Doyle JJ, et al: Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science, 2011; 332: 361–365.

  6. Takeda N, Inuzuka R, et al: Impact of pathogenic FBN1 variant types on the progression of aortic disease in patients with Marfan syndrome. Circ Genom Precis Med, 2018; 11: e002058.

  7. Loeys BL, Dietz HC, et al: The revised Ghent nosology for the Marfan syndrome. J Med Genet, 2010; 47: 476–485.

  8. Roman MJ, Devereux RB, et al: Two–dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol, 1989; 64: 507–512.

  9. 武田憲文：Marfan症候群と類縁疾患の診断と管理：オーバービュー．医学のあゆみ，2018; 264: 211–215.

  10. 武田憲文：疾患Review－マルファン症候群．SRL宝函，2019; 40: 21–30.

  11. Lacro RV, Dietz HC, et al: Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med, 2014; 371: 2061–2071.

  12. Ando M, Yamauchi H, et al: Long–term outcome after the original and simple modified technique of valve–sparing aortic root reimplantation in Marfan–based population, David V University of Tokyo modification. J Cardiol, 2016; 67: 86–91.

  13. 武田憲文：遺伝性大動脈瘤・解離のPrecision Medicine．心臓，2018; 50: 884–889.